SARS-CoV-2 alpha variant: is it really more deadly? A population level observational study

Candace Makeda Moore, Ruslan Sergienko, Ronen Arbel
doi: https://doi.org/10.1101/2021.08.17.21262167

Article Information

doi 
https://doi.org/10.1101/2021.08.17.21262167
History 
  • August 18, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Candace Makeda Moore, MD.1,*,
  2. Ruslan Sergienko, MA2 and
  3. Ronen Arbel, PhD.1
  1. 1Maximizing Health Outcomes Research Lab, Sapir College, Sderot, Israel
  2. 2Department of Health Policy and Management, Ben-Gurion University of the Negev, Beer Sheva, Israel
  1. ↵*Corresponding author:
    Candace Makeda Moore, M.D., Research Coordinator, Maximizing Health Outcomes Research Lab, Sapir College, Sderot, Israel Tel: (972) 52 353 1419; Fax: (972) 3 6916340; E-mail: doctormakeda{at}gmail.com
Back to top
Posted August 18, 2021.
Download PDF
Data/Code
Email
SARS-CoV-2 alpha variant: is it really more deadly? A population level observational study
Candace Makeda Moore, Ruslan Sergienko, Ronen Arbel
medRxiv 2021.08.17.21262167; doi: https://doi.org/10.1101/2021.08.17.21262167
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area